Stocktoria
KYNTRA BIO, INC. KYNB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-11-14
KYNTRA BIO, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.4M | $29.6M | $46.8M | $140.7M | $235.3M |
| R&D expense | $23.5M | $95.7M | $266.5M | $296.8M | $387.0M |
| SG&A expense | $27.7M | $49.3M | $86.5M | $124.7M | $123.9M |
| Operating income | -$45.9M | -$150.4M | -$322.7M | -$301.0M | -$288.5M |
| Interest expense | $8.8M | $8.2M | $8.1M | $1.4M | $1.1M |
| Income tax | -$90,000 | -$269,000 | -$252,000 | $358,000 | $347,000 |
| Net income | $183.5M | -$47.6M | -$284.2M | -$293.7M | -$290.0M |
| EPS (diluted) | $45.37 | $-11.89 | $-2.92 | $-3.14 | $-3.14 |
| Operating cash flow | -$4.8M | -$138.0M | -$315.0M | -$145.9M | -$82.2M |
| Free cash flow | -$4.8M | -$138.3M | -$317.5M | -$149.7M | -$87.4M |
| Cash & equivalents | $47.9M | $50.5M | $81.6M | $155.7M | $171.2M |
| Inventory | $3.7M | $3.2M | $17.2M | $40.4M | $31.0M |
| Total assets | $119.6M | $214.5M | $423.5M | $610.1M | $773.8M |
| Total liabilities | $115.1M | $398.2M | $585.7M | $611.6M | $544.7M |
| Shareholders' equity | -$30.0M | -$225.6M | -$204.2M | -$21.4M | $229.1M |
Source: SEC EDGAR filings · CIK 0000921299 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.